Beta-interferon, retinoids and tamoxifen as maintenance therapy in metastatic breast cancer. A pilot study

F. Recchia, S. Rea, P. Pompili, D. Casucci, M. Jaffrain Rea, F. Rizzo, A. Gulino, L. Frati

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Background: Chemotherapy (CT), fundamental for the treatment of metastatic breast cancer (MBC), rarely cures, due to the presence of minimal residual disease (MRD). Based on the synergistic antiproliferative effect of interferon, retinoids and tamoxifen on breast cancer cell lines we designed a pilot study to test if a combination of beta-interferon (β-IFN), retinoids and tamoxifen could improve the progression free survival and overall survival in patients (PTS) treated with CT for MBC. Methods: Thirty-six patients, with stage IV carcinoma of the breast, were treated with a combination of Cyclophosphamide, 5-fluorouracil, 4-epidoxorubicin, vincristine and prednisone every 3 weeks for six courses (FECPV), followed by two courses of methotrexate, mitomycin-c and mitoxantrone (MMM). Treatment was continued, in response, with low dose β-interferon, retynil palmitate and tamoxifen until disease relapse. Results: Among 36 evaluable PTS, 23 achieved a clinical response (64%) (95% c.i. 48 x 80%), 7 had disease stability (19%), and 6 (17%) progressed. Leukopenia occurred in 15 patients, thrombocytopenia in six, and anemia in 11. 16 patients had nausea/vomiting; stomatitis was observed in nine patients and diarrhea in three. Toxicity of maintenance therapy was mild and mainly hepatic. Median response duration was 31 months (range 5-75+). Median overall survival was 32 months (9-83+). Conclusions: Our study shows that this regimen is feasible and shows activity in MBC with an acceptable toxicity.

Original languageEnglish
Pages (from-to)603-610
Number of pages8
JournalClinica Terapeutica
Volume146
Issue number10
Publication statusPublished - 1995

Fingerprint

Interferon-beta
Retinoids
Tamoxifen
Breast Neoplasms
Interferons
Therapeutics
Drug Therapy
Mitoxantrone
Epirubicin
Stomatitis
Survival
Palmitates
Leukopenia
Residual Neoplasm
Mitomycin
Vincristine
Prednisone
Methotrexate
Fluorouracil
Thrombocytopenia

Keywords

  • beta-IFN
  • chemotherapy
  • metastatic breast cancer
  • retinoids
  • tamoxifen

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Recchia, F., Rea, S., Pompili, P., Casucci, D., Jaffrain Rea, M., Rizzo, F., ... Frati, L. (1995). Beta-interferon, retinoids and tamoxifen as maintenance therapy in metastatic breast cancer. A pilot study. Clinica Terapeutica, 146(10), 603-610.

Beta-interferon, retinoids and tamoxifen as maintenance therapy in metastatic breast cancer. A pilot study. / Recchia, F.; Rea, S.; Pompili, P.; Casucci, D.; Jaffrain Rea, M.; Rizzo, F.; Gulino, A.; Frati, L.

In: Clinica Terapeutica, Vol. 146, No. 10, 1995, p. 603-610.

Research output: Contribution to journalArticle

Recchia, F, Rea, S, Pompili, P, Casucci, D, Jaffrain Rea, M, Rizzo, F, Gulino, A & Frati, L 1995, 'Beta-interferon, retinoids and tamoxifen as maintenance therapy in metastatic breast cancer. A pilot study', Clinica Terapeutica, vol. 146, no. 10, pp. 603-610.
Recchia F, Rea S, Pompili P, Casucci D, Jaffrain Rea M, Rizzo F et al. Beta-interferon, retinoids and tamoxifen as maintenance therapy in metastatic breast cancer. A pilot study. Clinica Terapeutica. 1995;146(10):603-610.
Recchia, F. ; Rea, S. ; Pompili, P. ; Casucci, D. ; Jaffrain Rea, M. ; Rizzo, F. ; Gulino, A. ; Frati, L. / Beta-interferon, retinoids and tamoxifen as maintenance therapy in metastatic breast cancer. A pilot study. In: Clinica Terapeutica. 1995 ; Vol. 146, No. 10. pp. 603-610.
@article{420640296a4b4c0f9869050f9951c4e0,
title = "Beta-interferon, retinoids and tamoxifen as maintenance therapy in metastatic breast cancer. A pilot study",
abstract = "Background: Chemotherapy (CT), fundamental for the treatment of metastatic breast cancer (MBC), rarely cures, due to the presence of minimal residual disease (MRD). Based on the synergistic antiproliferative effect of interferon, retinoids and tamoxifen on breast cancer cell lines we designed a pilot study to test if a combination of beta-interferon (β-IFN), retinoids and tamoxifen could improve the progression free survival and overall survival in patients (PTS) treated with CT for MBC. Methods: Thirty-six patients, with stage IV carcinoma of the breast, were treated with a combination of Cyclophosphamide, 5-fluorouracil, 4-epidoxorubicin, vincristine and prednisone every 3 weeks for six courses (FECPV), followed by two courses of methotrexate, mitomycin-c and mitoxantrone (MMM). Treatment was continued, in response, with low dose β-interferon, retynil palmitate and tamoxifen until disease relapse. Results: Among 36 evaluable PTS, 23 achieved a clinical response (64{\%}) (95{\%} c.i. 48 x 80{\%}), 7 had disease stability (19{\%}), and 6 (17{\%}) progressed. Leukopenia occurred in 15 patients, thrombocytopenia in six, and anemia in 11. 16 patients had nausea/vomiting; stomatitis was observed in nine patients and diarrhea in three. Toxicity of maintenance therapy was mild and mainly hepatic. Median response duration was 31 months (range 5-75+). Median overall survival was 32 months (9-83+). Conclusions: Our study shows that this regimen is feasible and shows activity in MBC with an acceptable toxicity.",
keywords = "beta-IFN, chemotherapy, metastatic breast cancer, retinoids, tamoxifen",
author = "F. Recchia and S. Rea and P. Pompili and D. Casucci and {Jaffrain Rea}, M. and F. Rizzo and A. Gulino and L. Frati",
year = "1995",
language = "English",
volume = "146",
pages = "603--610",
journal = "Clinica Terapeutica",
issn = "0009-9074",
publisher = "Societa Editrice Universo",
number = "10",

}

TY - JOUR

T1 - Beta-interferon, retinoids and tamoxifen as maintenance therapy in metastatic breast cancer. A pilot study

AU - Recchia, F.

AU - Rea, S.

AU - Pompili, P.

AU - Casucci, D.

AU - Jaffrain Rea, M.

AU - Rizzo, F.

AU - Gulino, A.

AU - Frati, L.

PY - 1995

Y1 - 1995

N2 - Background: Chemotherapy (CT), fundamental for the treatment of metastatic breast cancer (MBC), rarely cures, due to the presence of minimal residual disease (MRD). Based on the synergistic antiproliferative effect of interferon, retinoids and tamoxifen on breast cancer cell lines we designed a pilot study to test if a combination of beta-interferon (β-IFN), retinoids and tamoxifen could improve the progression free survival and overall survival in patients (PTS) treated with CT for MBC. Methods: Thirty-six patients, with stage IV carcinoma of the breast, were treated with a combination of Cyclophosphamide, 5-fluorouracil, 4-epidoxorubicin, vincristine and prednisone every 3 weeks for six courses (FECPV), followed by two courses of methotrexate, mitomycin-c and mitoxantrone (MMM). Treatment was continued, in response, with low dose β-interferon, retynil palmitate and tamoxifen until disease relapse. Results: Among 36 evaluable PTS, 23 achieved a clinical response (64%) (95% c.i. 48 x 80%), 7 had disease stability (19%), and 6 (17%) progressed. Leukopenia occurred in 15 patients, thrombocytopenia in six, and anemia in 11. 16 patients had nausea/vomiting; stomatitis was observed in nine patients and diarrhea in three. Toxicity of maintenance therapy was mild and mainly hepatic. Median response duration was 31 months (range 5-75+). Median overall survival was 32 months (9-83+). Conclusions: Our study shows that this regimen is feasible and shows activity in MBC with an acceptable toxicity.

AB - Background: Chemotherapy (CT), fundamental for the treatment of metastatic breast cancer (MBC), rarely cures, due to the presence of minimal residual disease (MRD). Based on the synergistic antiproliferative effect of interferon, retinoids and tamoxifen on breast cancer cell lines we designed a pilot study to test if a combination of beta-interferon (β-IFN), retinoids and tamoxifen could improve the progression free survival and overall survival in patients (PTS) treated with CT for MBC. Methods: Thirty-six patients, with stage IV carcinoma of the breast, were treated with a combination of Cyclophosphamide, 5-fluorouracil, 4-epidoxorubicin, vincristine and prednisone every 3 weeks for six courses (FECPV), followed by two courses of methotrexate, mitomycin-c and mitoxantrone (MMM). Treatment was continued, in response, with low dose β-interferon, retynil palmitate and tamoxifen until disease relapse. Results: Among 36 evaluable PTS, 23 achieved a clinical response (64%) (95% c.i. 48 x 80%), 7 had disease stability (19%), and 6 (17%) progressed. Leukopenia occurred in 15 patients, thrombocytopenia in six, and anemia in 11. 16 patients had nausea/vomiting; stomatitis was observed in nine patients and diarrhea in three. Toxicity of maintenance therapy was mild and mainly hepatic. Median response duration was 31 months (range 5-75+). Median overall survival was 32 months (9-83+). Conclusions: Our study shows that this regimen is feasible and shows activity in MBC with an acceptable toxicity.

KW - beta-IFN

KW - chemotherapy

KW - metastatic breast cancer

KW - retinoids

KW - tamoxifen

UR - http://www.scopus.com/inward/record.url?scp=0029550035&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029550035&partnerID=8YFLogxK

M3 - Article

VL - 146

SP - 603

EP - 610

JO - Clinica Terapeutica

JF - Clinica Terapeutica

SN - 0009-9074

IS - 10

ER -